Head of policy @CivicaRx, but tweets are my own.
Washington, DC
Joined October 2013
- Tweets3K
- Following470
- Followers1.3K
- Likes822
Allan Coukell retweeted
Vaccinating Health Care Supply Chains Against Market Failure: The Case of Civica Rx: nej.md/465buYs @CivicaRx @SSMHealth
Allan Coukell retweeted
.@Forbes released its 2023 philanthropy scorecard and once again, @johnarnold and @LauraArnoldFdn earned the highest score — a rare 5 — for their charitable giving. Only 11 people from the #Forbes400 have given away more than 20% of their wealth: bit.ly/3RGcRsI
Or 300 students at U Mass. Just saying.
$43,000,000 was spent in three years with very little research or anything else to show for it. 130 students could have had a totally free BU education (plus room/board) for four years instead . Or 10 faculty chairs could have been endowed in perpetuity. What a waste of money.
Allan Coukell retweeted
"Civica Rx significantly increased supply security and lowered the cost in aggregate...these medications are critical to patient care & have been prone to shortages." - Carter Dredge, @SSMHealth @nejmcatalyst @CivicaRx ssmhealth.com/newsroom/2023/…
Allan Coukell retweeted
Big PBMs say “Drugmakers alone have the power to set prices.”
Then how is that the same PBM set five different prices for the same drug, at the same pharmacy, on the same day, where the delta between the bookends had an over 10x difference?
Our latest: 3axisadvisors.com/projects/2…
Allan Coukell retweeted
Do Plan Sponsors Understand How Their PBMs Make Money?
My $0.02 on how #PBMs' profit model has evolved—and why a plan sponsor can feel satisfied with PBM transparency while remaining unaware of how its PBM actually earns money.
@psgconsults
drugch.nl/3EIogQT
Allan Coukell retweeted
“Across a selection of these so-called specialty generic drugs, Cigna and CVS’s prices were at least 24 times higher on average than roughly what the medicines’ manufacturers charge, the @WSJ found.” - @joewalkerWSJ
wsj.com/health/healthcare/ge…
Allan Coukell retweeted
"Civica is the only pharma created specifically to address drug shortages. The drugs we deliver are not chosen for return-on-investment. They are chosen by hospitals because they are in shortage or at risk of shortage." @coukell, @CivicaRx at U.S. Subcommittee on Health hearing
Allan Coukell retweeted
ICYMI - @mganio_ASHP @coukell @CivicaRx @ASHPOfficial provided great recs on fixing the drug shortages problem during todays hearing energycommerce.house.gov/eve… – at Salt Lake City, UT
"Generic drugs should be cheap, but insurers are charging thousands of dollars for them" (NB - in place of "insurer" read "PBM," though sometimes they are one and the same.) wsj.com/health/healthcare/ge…
It has been a busy few years…
Five years in less than 10 minutes. We invite you to watch and learn more about the power of partnership and collaboration. @CivicaRx vimeo.com/861643603/a1aea91e…
Can’t say we weren’t warned.
You’re unable to view this Post because this account owner limits who can view their Posts. Learn more
Allan Coukell retweeted
Ukraine came to the aid of the United States after we were attacked on 9/11 and deployed troops to support the ISAF mission in Afghanistan for almost 14 years
Allan Coukell retweeted
Daily reminder that the insulin I need to survive is still $2,267.99 every 3 months.
Insurance is not the answer to unaffordable insulin, as insurance was the reason it took 23 DAYS to fill this RX. W/o insulin, I’d be dead in 2.
Insulin should be free.
ALT CVS receipt for 7 vials of Humalog insulin priced at $2,267.99.
Allan Coukell retweeted
Day 16:
Insurance is still refusing to fill the insulin that keeps me alive.
My “options” are: pay $2,267.99 for a 3-month supply of insulin or die.
This is why insulin PRICES, not copays, must be capped. Insurance is not the answer to the insulin affordability crisis.
Insurance is AGAIN refusing to fill the Humalog insulin that’s kept me alive for 27 years.
I am deathly allergic to the Novolog they want me on.
I HAVE A PRIOR AUTH FOR HUMALOG.
So I pay $2500 out of pocket or I die.
Do I have that right, @CareFirst @CVSHealth?
Great to see a nonprofit pharma bringing a critical public health product to market
Just approved by @US_FDA please welcome:
RiVive
3mg naloxone nasal spray
by NON-PROFIT Harm Reduction Therapeutics
STOP SAYING "NARCAN" because now you have a 35% cheaper option.
Donations: 200,000 free doses via @RemedyAlliance!!
ALT Prototype packaging
ALT Final production packaging
Allan Coukell retweeted
The large number of recalls these 503b's generate are difficult to manage in hospitals.
FDA inspection underscores problem at major U.S. compounder behind hospital drug recalls statnews.com/pharmalot/2023/… via @statnews
Allan Coukell retweeted
The "Big 3" insulin makers drew favorable news coverage for "cutting prices to $25/vial."
But a new survey reveals those "cuts" haven't reached most patients.
@t1international: Most patient advocates "have been unable to get the promised $25 insulin."
🔗: warren.senate.gov/imo/media/…
Americans without health insurance pay an average of $98 for Eli Lilly’s generic insulin despite the company’s May 1 pledge to cut its list price to $25 per vial, according to a survey of more than 300 U.S. pharmacies. aol.com/uninsured-us-patient…
